Physician profile
Steven J Simonte
NPI 1487657615
$832.80
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $543 · 2020: $104 · 2021: $69.69 · 2022: $116.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $146.90 | 2019-2022 | |
| Kaleo, INC. | $80.59 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $75.45 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $68.08 | 2019-2022 | |
| Glaxosmithkline, LLC. | $64.78 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.48 | 2020-2021 | |
| Csl Behring | $53.42 | 2019 | |
| Pfizer INC. | $53.33 | 2019 | |
| Alk-Abello, INC | $52.05 | 2019-2022 | |
| Pharming Healthcare, INC. | $51.23 | 2019-2022 | |
| Genentech USA, INC. | $37.30 | 2019 | |
| Covis Pharma Gmbh | $26.70 | 2020 | |
| Genzyme Corporation | $25.89 | 2019 | |
| Abbvie INC. | $25.10 | 2022 | |
| Circassia INC. | $15.50 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Simonte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.